# A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer

> **NCT02131506** · PHASE1 · TERMINATED · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 11 (actual)

## Conditions studied

- HER-2 Positive Breast Cancer
- Malignant Neoplasm of Breast

## Interventions

- **DRUG:** Lapatinib, Caelyx

## Key facts

- **NCT ID:** NCT02131506
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Safety reasons
- **Last updated:** 2016-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02131506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02131506, "A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02131506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*